"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to SMMT. [ FAQ on what and how to ask] For non-SMMT questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Mr. Robert W. Duggan and Dr. Mahkam Zanganeh D.D.S., M.B.A.
Headquarter: 601 Brickell Key Drive, Suite 1000, Miami, FL, United States, 33131
Industry: Biotechnology, Investment Track: Biotech - Cancer - Molecule, Employees: 265
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
My Watchlist
